Barclays Starts IDEXX Laboratories (IDXX) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts IDXX Hot Sheet
Price: $672.04 --0%
Rating Summary:
13 Buy, 9 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Rating Summary:
13 Buy, 9 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Join SI Premium – FREE
Barclays analyst Glen Santangelo initiates coverage on IDEXX Laboratories (NASDAQ: IDXX) with a Overweight rating and a price target of $850.00.
For an analyst ratings summary and ratings history on IDEXX Laboratories click here. For more ratings news on IDEXX Laboratories click here.
Shares of IDEXX Laboratories closed at $714.10 yesterday.
You May Also Be Interested In
- IDEXX Laboratories (IDXX) PT Raised to $770 at Jefferies
- H.C. Wainwright Starts Kardigan Inc (KARD) at Buy
- Bernstein SocGen Group Starts Pfizer Ltd (PFIZ:IN) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
